Lithuanian-based medtech startup Sentante raises €6 million in seed funding. Leading this round was Practica Capital, with the EIC fund participating.
The planned clinical trial of the Sentante robotic system and the setup for its commercial launch in particular international markets will be funded by the company with the earnings from the financing.
Edvardas Satkauskas, co-founder and CEO of Sentante said, “We appreciate the trust and support from our new investors to help us reach our critical milestones. Sentante will revolutionize the way endovascular procedures are performed and we are looking forward to introducing our robotic system into clinical practice, Our innovative robotic technology will digitize and improve the procedure by empowering physicians to work with better accuracy, precision, and safety.”
Over six million procedures are carried out each year in the endovascular care of cardiovascular illnesses, including peripheral artery disease, heart attacks, and stroke. For more than forty years, the process stays essentially the same, despite the expansion of the market and advancements in the area.
Tomas Andriuškevičius, partner at Practica Capital said, “We are thrilled to partner with Sentante, a company that aligns perfectly with our philosophy of supporting transformative innovations. With their unique teleoperated endovascular intervention system, Sentante is set to redefine surgical practices globally, improving both patient outcomes and the well-being of medical professionals. This investment underscores our commitment to advancing healthcare technologies that have the potential to create a significant, positive impact worldwide,”.
Svetoslava Georgieva, Chair of the EIC Fund Board, added: “The EIC Fund aims at backing European innovators in scaling their journey and Sentante is a great example of how the European Union is helping top innovators. The EIC Fund’s ambitious commitment, alongside other investors, is an important step to boost their development.”
Sentante, which was founded in 2017, can be seamlessly integrated into the current treatment process because it makes use of the same medical equipment as a manual approach. They anticipate that the first-in-human clinical research will begin later in 2024, which will be a significant turning point showcasing Sentante’s skills in peripheral vascular treatments.